Delivery Order SPE2DB25D2204-SPE2DB25FTHBR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by October 20, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Envarsus XR 4 mg tablets in a quantity of 100 units, with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for ultimate completion by October 20, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a $1,711.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Envarsus XR 4 mg tablets (100-count units) with an ultimate completion date of August 14, 2025. This non-set-aside competitive award was issued on July 24, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical...
- The Defense Logistics Agency has awarded a delivery order valued at $1,711.95 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count packaging). This firm fixed-price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by October 21, 2025. The contract will be performed at the awardee's corporate headquarters in Conshohocken, Pennsylvania, where AmerisourceBergen maintains operations as a primary pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,718.48 for 100 tablets of Envarsus XR 1 mg on July 28, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price, competitively awarded contract involves pharmaceutical delivery to support federal medical procurement needs. The contract does not include a set-aside designation and is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $2,148.10 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Envarsus XR 1 mg tablets (100-count). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 17, 2025, and represents a continuation of AmerisourceBergen's substantial pharmaceutical supply relationship with federal medical procurement. The work will be performed at the company's...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a contract ceiling value of $2,148.10. This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and represents a non-competitive set-aside award. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $1,718.48 delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg on September 24, 2025, with an ultimate completion date of October 16, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Department of Defense Medical Supply Chain has awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets in a quantity of 100 units, with a contract ceiling value of $3,423.90. This delivery order, awarded on August 4, 2025, with an ultimate completion date of August 25, 2025, utilizes firm fixed price terms and carries no set-aside designation, indicating competitive award to this pharmaceutical distributor. The work will be performed at...
- The Defense Logistics Agency awarded a $3,423.90 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages). This firm fixed price, non-set-aside contract is scheduled for completion by September 10, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs through the agency's established...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTHBRDelivery Order
The Defense Logistics Agency awarded a $1,711.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 4 mg on September 24, 2025, with completion scheduled for October 16, 2025. This non-set-aside competitive award is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters. The delivery order represents a specific pharmaceutical requirement within the federal medical supply chain supporting Defense Department healthcare needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal military and veteran healthcare systems, AmerisourceBergen maintains a comprehensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's status as a prime vendor through this substantial IDC enables it to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with flexible pharmaceutical procurement worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/24/25 |